RedPath’s PathFinderTG is a molecular-based test that allows definitive diagnosis of very small specimens.  Using the original specimen, the PathFinderTG test obtains a genetic fingerprint of mutations in certain cancer types, including GI tract, pancreas, head and neck, brain, breast, genitourinary, and gynecologic tracts.

Because the results offer early and definitive diagnosis, the test offers strong support for the right treatment plan for the individualized patient. PathFinderTG is clinically validated with an accuracy rate of up to 95%, depending on the assay.

The test can be performed on all routine hospital or clinical pathology materials, which means that your physician can utilize existing samples for testing and comparison purposes. Your samples will be sent to RedPath and a final report sent to your doctor within five to seven working days.